Utility of a Screening Test (MoCa) to Predict Amyloid Physiopathology in Mild Cognitive Impairment

  • María Florencia Clarens FLENI
  • Ismael Calandri FLENI, Buenos Aires, Argentina
  • María Belen Helou FLENI, Buenos Aires, Argentina
  • María Eugenia Martín
  • Patricio Chrem Méndez FLENI, Buenos Aires, Argentina
  • Lucia Crivelli FLENI, Buenos Aires, Argentina

Abstract

Introduction: The MoCa (Montreal Cognitive Assessment) Screening test has become relevant in recent years in the screening of patients with Mild Cognitive Impairment (MCI). It is important to seek and study simple and reliable tools in clinical practices that correlate with biological markers that have been used to predict conversion from MCI to AD. Objective: To analyze the MOCA and its cognitive sub-scores and the relationship with Amyloid pathophysiology in Alzheimer’s Disease. Methodology: 32 patients with MCI were studied, they were separated according positive (n: 20) and negative (n: 12) underlying amyloid pathology. The patients performed a extensive cognitive assessment that included MoCa Test. Results: MoCa Total Scores showed significantly different results between groups (p <0.001) as well as the Memory Score (MoCa MIS), the Executive (MoCa EIS), the Attentional Score (MoCa AIS)) (p < 0.001) and the Orientation Score (MoCa OIS)) (p < 0.05) with worse performance of patients with amyloid pathophysiology. Score of MoCa a cut-off point of < 24 was established, since the diagnostic sensitivity at this point was 83% and the specificity 70%. Conclusions: The MoCa is a useful tool to differentiate biomarker status in MCI. Future studies should study this tool in the prodromal phases of the disease.

Keywords: Alzheimer's Disease, Amyloid, Mild Cognitive Impairment, Neuropsychology, Dementia

References

Besser, L., Kukull, W., Knopman, D. S., Chui, H., Galasko, D., Weintraub, S., Jicha, G., Carlsson, C., Burns, J., Quinn, J., Sweet, R. A., Rascovsky, K., Teylan, M., Beekly, D., Thomas, G., Bollenbeck, M., Monsell, S., Mock, C., Hua, X., Thomas, N., Robichaud, E., Dean, M., Hubbard, J., Jacka, M., Schwabe-Fry, K., Wu, J., Phelps, C. & Morris, J. C. (2018). Version 3 of the National Alzheimer’s Coordinating Center’s Uniform Data Set. Alzheimer disease and associated disorders, 32(4), 351–358. https://doi.org/10.1097/WAD.0000000000000279

Clarens, M. F., Crivelli, L., Calandri, I., Chrem, P., Martin, M. E., Russo, M. J., Campos, J., Surace, E., Vásquez, S., Sevlever, G. & Allegri, R. F. (2020). Neuropsychological profile of Alzheimer’s disease based on amyloid biomarker findings results from a South American cohort. Applied Neuropsychology: Adult, 1–6. https://doi.org/10.1080/23279095.2020.1756816

Folstein, M. F., Folstein, S. E. & McHugh, P. R. (1975). “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. Journal of psychiatric research, 12(3), 189–198. https://doi.org/10.1016/0022-3956(75)90026-6

Hachinski, V. C., Iliff, L. D., Zilhka, E., Du Boulay, G. H., McAllister, V. L., Marshall, J., Rusell, R. W. & Symon, L. (1975). Cerebral blood flow in dementia. Archives of neurology, 32(9), 632–637. https://doi.org/10.1001/archneur. 1975.00490510088009

Hugues, M., Romey, G., Duval, D., Vincent, J. P. & Lazdunski, M. (1982). Apamin as a selective blocker of the calcium-dependent potassium channel in neuroblastoma cells: voltage-clamp and biochemical characterization of the toxin receptor. Proceedings of the National Academy of Sciences, 79(4), 1308–1312. https://doi.org/10.1073/pnas.79.4.1308

Julayanont, P., Brousseau, M., Chertkow, H., Phillips, N. & Nasreddine, Z. S. (2014). Montreal Cognitive Assessment Memory Index Score (MoCa-MIS) as a Predictor of Conversion from Mild Cognitive Impairment to Alzheimer’s Disease. Journal of the American Geriatrics Society, 62(4), 679–684. https://doi.org/10.1111/jgs.12742

Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. & Chertkow, H. (2005). The Montreal Cognitive Assessment, MoCa: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society, 53(4), 695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.x

Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G. & Kokmen, E. (1999). Mild cognitive impairment: clinical characterization and outcome. Archives of neurology, 56(3), 303–308. https://doi.org/10.1001/archneur.56.3.303

Weintraub, S., Besser, L., Dodge, H. H., Teylan, M., Ferris, S., Goldstein, F. C., Kramer, J., Loewenstein, D., Marson, D., Mungas, D., Salmon, D., Welsh-Bohmer, K., Zhou, X.-H., Shirk, S. D., Atri, A., Kukull, W. A., Phelps, C. & Morris, J. C. (2018). Version 3 of the Alzheimer Disease Centers’ neuropsychological test battery in the Uniform Data Set (UDS). Alzheimer disease and associated disorders, 32(1), 10–17. https://doi.org/10.1097/WAD.0000000000000223

Downloads

Download data is not yet available.
Published
2020-12-09
How to Cite
Clarens, M. F., Calandri, I., Helou, M. B., Martín, M. E., Chrem Méndez, P., & Crivelli, L. (2020). Utility of a Screening Test (MoCa) to Predict Amyloid Physiopathology in Mild Cognitive Impairment. Journal of Applied Cognitive Neuroscience, 1(1), 87-91. Retrieved from https://revistascientificas.cuc.edu.co/JACN/article/view/3323